Cerebellar metastasis of ovarian cancer: a case report

Ovarian cancer (OC) is the deadliest gynecological tumor, representing the fifth cause of death from cancer among women, as 7.2 deaths per 100,000 women are reported every year in the USA [1]. OC is a “silent killer,” being metastatic at presentation in about 62% of cases; indeed, its diagnosis often occurs in advanced stage (FIGO stage III–IV) [1, 2].

The most common sites of metastasis are the peritoneum, liver, and lymph nodes [3, 4]. Only occasionally, bones could be involved [3‐5]. Conversely, brain metastases (BMs) are rare; they are globally reported in 3.3–4% of patients, as confirmed by the Multicenter Italian Trials in Ovarian cancer (MITO) analysis [5, 6]. A progressive increase in BMs incidence has been observed, probably due to the improvement in diagnostic techniques and in patients’ survival with new therapeutic options [7, 8]. The identification of BMs at presentation is still exceptional (only 1% of patients), as emerged from the retrospective study of Gardner et al. [9]. BMs seem to be more frequent in patients with OC with poorly differentiated histology (serous, clear cell, undifferentiated) and advanced stage at diagnosis, but they may occur even in the IC stage [6, 10]. It is reported that patients with OC with a BRCA1/2 mutation are more prone to develop both visceral and BMs compared with BRCA wild-type patients [11‐14]. As emerged from the retrospective study of Teckie et al., most patients presenting with encephalic metastasis have a single metastasis (about 46.7%) while 26.7% have four metastases or more; leptomeningeal disease is still rarely reported in ovarian cancer [14]. BMs are related with poor prognosis [5, 13], and, regardless of BRCA status, patients with OC with lung, bone, or brain metastases have a worse prognosis compared with those who have liver metastases [15].

The current standard treatment of epithelial ovarian cancer (EOC) of all histological subtypes involves primary optimal debulking surgery followed by cisplatin-based chemotherapy. Metastasis to the central nervous system (CNS) from OC has been postulated to occur via direct hematogenous seeding through Virchow–Robin perivascular spaces, through retrograde lymphatic spread in the case of meningeal involvement, or by direct invasion into the central nervous system after bony involvement [16].

The management of BMs requires a multimodal approach [10, 16]. Surgery associated with chemotherapy and/or radiotherapy could ensure not only a better effective response, but also a longer survival [10, 16‐19].

Herein we report on the case of a patient suffering from high-grade serous ovarian carcinoma whose symptoms at presentation and initial diagnosis were related with a cerebellar metastasis. The metastasis and the primary tumor were surgically treated. Subsequently, the patient underwent adjuvant chemotherapy and maintenance with PARP inhibitor (PARPi) niraparib.

On 13 September 2021, a young Caucasian woman under 50 years old presented to the emergency department with a headache that had been recurring for about a month and worsening. The patient did not have side deficits or other neurological disorders. Physical examination showed no major symptoms, and blood tests performed in an emergency revealed no criticality. She did not describe weight loss or other symptoms suggesting cancer.

Brain computed tomography (CT) scans revealed the presence of a left cerebellar voluminous cystic lesion, with mass effect and obstructive hydrocephalus (Fig. 1). She was an active smoker and her medical history included hypertension, hypercholesterolemia under treatment, gastroesophageal reflux disease, and an episode of non-ST-segment elevation myocardial infarction (NSTEMI) treated with stent placement in July 2020. She did not report major surgical interventions and denied family history of oncological pathologies.

On 16 September 2021, she underwent neurosurgery for the removal of the cerebellar lesion.

On histopathological examination, a poorly differentiated adenocarcinoma with papillary aspects was found (Fig. 2C, D). Morphology and immunophenotype (CK7+, ER+/−, PR−/+, CD10−/+, c-ERBB2−, TTF1−, CDX-2−, CK20−, β-catenin−) were consistent with a metastasis from an ovarian/gynecological primitivity (Fig. 2E–G).

Contrast-enhanced chest and abdominal computed tomography (CT) scans reported an oval-shaped neoformation of 12.9 × 7.7 cm with bumpy contours located in the right adnexal area, which was suspicious for ovarian carcinoma; an oval-shaped solid formation of 5.8 × 5.6 × 3.7 cm was also found in the left adnexal area, while no other pathological findings were documented elsewhere (Fig. 1). The lesions were confirmed with magnetic resonance imaging (MRI) and transvaginal gynecologic ultrasound scans. In September 2021, serum tumor markers were carcinoembryonic antigen (CEA) 5.8 ng/mL [normal value (n.v.) 0–5 ng/mL] and cancer antigen 125 (CA125) 614.6 U/mL (n.v. 0–35 U/mL).

In October 2021, she underwent laparoscopic bilateral adnexectomy and peritoneal washing cytology. On histopathological examination, the peritoneal fluid was negative for neoplastic cells. In both ovaries there was evidence of high-grade, infiltrating serous carcinomas, with lymphovascular invasion and extension to the serosa (Fig. 2A and B). The final stage was pT1c2 cN0 pM1b (FIGO stage IV). No BRCA mutations were detected. On 2 November 2021, the postsurgical chest and abdominal CT revealed no evidence of residual disease.

On 8 November 2021, the brain MRI showed in the left deep cerebellar hemisphere—the site of surgery—an area with fluid content and thickened margins avidly enhancing after contrast administration. At this time, serum tumor markers were CEA 5.4 ng/mL and CA 125 99.8 U/mL. The case was discussed in a multidisciplinary meeting with no indication for brain radiotherapy (RT).

From December 2021 to April 2022, the patient underwent first-line chemotherapy with carboplatin and paclitaxel three-weekly administrations, standard doses, that was well tolerated in the absence of significant side effects. On 23 December 2021, about 2.5 months after surgery, serum tumor markers were all in the range of normality.

In February 2022, the multidisciplinary team placed the indication to repeat brain MRI with the aim of evaluating whether to perform brain stereotactic RT. In the meantime, bevacizumab was not added to chemotherapy. Thoracic and abdominal CT scan performed on 24 February 2022 confirmed no evidence of residual disease. On 17 March 2022, the brain MRI showed findings consistent with postsurgical sequelae and RT was not confirmed.

On March 2022, the patient ended chemotherapy after six administrations with persistence of the complete response obtained from surgery. On 28 April 2022, she started maintenance therapy with PARPi niraparib 200 mg daily, representing the standard schedule and dose for her weight. The first CT scan after starting the maintenance therapy (June 2022) confirmed complete response. On 21 July 2022, the serum CEA levels were 5.4 ng/mL while CA125 levels accounted for 16.8 U/mL. Brain MRI, repeated in April 2022 and in July 2022, were negative for disease. The patient is alive and continues maintenance treatment with good quality of life at the time of writing.

BMs in ovarian cancer are rare but complex for diagnosis and management as they impact the prognosis of patients. This case focuses both on diagnosis and treatment, emphasizing the importance of a multimodal approach in a multidisciplinary team.

In this case, the presentation with a cerebellar metastasis of ovarian carcinoma at diagnosis in exceptionally rare. The diagnosis was based on morphological and immunohistochemical data, confirmed by clinical and radiological findings.

Furthermore, even in the absence of a consensus-based treatment protocol, the multimodal therapeutic strategy is showing excellent results, with surgery upfront and systemic therapy later. Among the maintenance strategies for OC, the PARPi niraparib has already demonstrated its efficacy in the treatment of BMs in animal models, being able to overcome the blood–brain-barrier [20]. The case of a patient on maintenance therapy with niraparib who was in remission for over 17 months with an excellent quality of life was reported [21].

This case represents an example of successful personalized multimodal diagnostic and therapeutic approach in an atypical presentation of stage IV ovarian cancer with a cerebellar metastasis at diagnosis, that has warranted favorable results in the control of onset symptoms and metastatic disease.